3-(2-{3-[(3,4-dimethoxybenzenesulfonylamino)methyl]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester | 1203719-42-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-{3-[(3,4-dimethoxybenzenesulfonylamino)methyl]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-[2-[[3-[[(3,4-dimethoxyphenyl)sulfonylamino]methyl]benzoyl]amino]ethyl]piperidine-1-carboxylate
• CAS: 1203719-42-9
• 化学式: C₂₈H₃₉N₃O₇S
• 分子量: 561.7
• InChiKey: VONUXXGCKZXUQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-(2-{3-[(3,4-dimethoxybenzenesulfonylamino)methyl]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester 在 Bond Elut SCX 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以68.9%的产率得到3-[(3,4-dimethoxybenzenesulfonylamino)methyl]-N-(2-piperidin-3-ylethyl)benzamide hydrochloride
  参考文献：
  名称：

  Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase

  摘要：

  A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.

  DOI：

  10.1021/jm9014263
• 作为产物：
  描述：

  2-(N-Boc-3-哌啶基)乙胺 、 3-[(3,4-dimethoxybenzenesulfonylamino)methyl]benzoic acid 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以67.4%的产率得到3-(2-{3-[(3,4-dimethoxybenzenesulfonylamino)methyl]benzoylamino}ethyl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Hit to Lead Account of the Discovery of Bisbenzamide and Related Ureidobenzamide Inhibitors of Rho Kinase

  摘要：

  A highly selective series of bisbenzamide inhibitors of Rho-associated coiled-coil forming protein kinase (ROCK) and a related ureidoberizamide series, both identified by high throughput screening (HTS), are described. Details of the lilt validation and lead generation process, Including structure-activity relationship (SAR) studies, a selectivity assessment, target-independent profiling (TIP) results, and an analysis of functional activity using a rat aortic ring assay are discussed.

  DOI：

  10.1021/jm9014263